Kimryn Rathmell, chair of medicine at Vanderbilt University Medical Center, received the Paragon Award for Research Excellence from the Doris Duke Foundation.
People with metastatic kidney cancer who orally took a live biotherapeutic product called CBM588 while in treatment with immunotherapy and enzymatic tyrosine kinase inhibitors experienced improved health outcomes, according to research from City of Hope.
